Drug intelligence / Profile preview

JNJ-64041757 + nivolumab

Development stage: Discontinued
Lead developer: Janssen Biotech
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JNJ-64041757 + nivolumab is a combination immunotherapy approach that pairs a live, attenuated, double-deleted (LADD) Listeria monocytogenes-based immunotherapy expressing human mesothelin (JNJ-64041757/JNJ-757) with nivolumab, a PD-1 immune checkpoint inhibitor. The combination was designed to potentially enhance anti-tumor immune responses by combining the mesothelin-specific T-cell responses induced by JNJ-757 with the immune checkpoint blockade provided by nivolumab.

Other names: pemlimogene merolisbac + nivolumab

Targets

MesothelinPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on JNJ-64041757 + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-64041757 + nivolumab.

Explore the full profile